Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Feb;147(2):558-560.e1.
doi: 10.1016/j.jaci.2020.10.032. Epub 2020 Nov 5.

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience

Paolo Gisondi  1 , Stefano Piaserico  2 , Luigi Naldi  3 , Paolo Dapavo  4 , Andrea Conti  5 , Piergiorgio Malagoli  6 , Angelo Valerio Marzano  7 , Federico Bardazzi  8 , Massimo Gasperini  9 , Simone Cazzaniga  10 , Antonio Costanzo  11 ; collaborators in the studies of COVID-19 pandemic
Collaborators, Affiliations
Multicenter Study

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience

Paolo Gisondi et al. J Allergy Clin Immunol. 2021 Feb.

Abstract

Introduction: Whether biologic therapies enhance the risk of coronavirus 2019 (COVID-19) or affect the disease outcome in patients with chronic plaque psoriasis remains to be ascertained.

Objective: We sought to investigate the incidence of hospitalization and death for COVID-19 in a large sample of patients with plaque psoriasis receiving biologic therapies compared with the general population.

Methods: This is a retrospective multicenter cohort study including patients with chronic plaque psoriasis (n = 6501) being treated with biologic therapy and regularly followed up at the divisions of dermatology of several main hospitals in the Northern Italian cities of Verona, Padua, Vicenza, Modena, Bologna, Piacenza, Turin, and Milan. Incidence rates of hospitalization and death per 10,000 person-months with exact mid-p 95% CIs and standardized incidence ratios were estimated in the patients with psoriasis and compared with those in the general population in the same geographic areas.

Results: The incidence rate of hospitalization for COVID-19 was 11.7 (95% CI, 7.2-18.1) per 10,000 person-months in patients with psoriasis and 14.4 (95% CI, 14.3-14.5) in the general population; the incidence rate of death from COVID-19 was 1.3 (95% CI, 0.2-4.3) and 4.7 (95% CI, 4.6-4.7) in patients with psoriasis and the general population, respectively. The standardized incidence ratio of hospitalization and death in patients with psoriasis compared with those in the general population was 0.94 (95% CI, 0.57-1.45; P = .82) and 0.42 (95% CI, 0.07-1.38; P = .19), respectively.

Conclusions: Our data did not show any adverse impact of biologics on COVID-19 outcome in patients with psoriasis. We would not advise biologic discontinuation in patients on treatment since more than 6 months and not infected with severe acute respiratory syndrome coronavirus 2 to prevent hospitalization and death from COVID-19.

Keywords: COVID-19; Psoriasis; biologics; interstitial pneumonia.

PubMed Disclaimer

References

    1. Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109 - PMC - PubMed
    1. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? [published online ahead of print March 18, 2020]. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.03.031. - DOI - PMC - PubMed
    1. Liu Y., Zhang C., Huang F., Yang Y., Wang F., Yuan J., et al. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev. 2020;7:1003–1011. - PMC - PubMed
    1. Russell B., Moss C., George G., Santaolalla A., Cope A., Papa S., et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022. - PMC - PubMed
    1. Feldmann M., Maini R.N., Woody J.N., Holgate S.T., Winter G., Rowland M., et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395:1407–1409. - PMC - PubMed

Publication types

Substances